| __timestamp | Iovance Biotherapeutics, Inc. | Supernus Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 9335772 | 72471000 |
| Thursday, January 1, 2015 | 12390000 | 89204000 |
| Friday, January 1, 2016 | 25602000 | 106010000 |
| Sunday, January 1, 2017 | 21262000 | 137905000 |
| Monday, January 1, 2018 | 28430000 | 159888000 |
| Tuesday, January 1, 2019 | 40849000 | 158425000 |
| Wednesday, January 1, 2020 | 60210000 | 200677000 |
| Friday, January 1, 2021 | 83664000 | 304759000 |
| Saturday, January 1, 2022 | 104097000 | 377221000 |
| Sunday, January 1, 2023 | 106916000 | 336361000 |
Unleashing the power of data
In the competitive landscape of biopharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for operational efficiency. This analysis compares the SG&A trends of Supernus Pharmaceuticals, Inc. and Iovance Biotherapeutics, Inc. from 2014 to 2023. Over this period, Supernus consistently outspent Iovance, with SG&A expenses peaking at approximately $377 million in 2022, a staggering 250% increase from 2014. In contrast, Iovance's SG&A expenses grew by over 1,000%, reaching around $107 million in 2023. This dramatic rise reflects Iovance's aggressive expansion and investment in its pipeline. Meanwhile, Supernus's more stable growth suggests a mature market strategy. Understanding these trends offers insights into each company's strategic priorities and market positioning. As the biopharma sector evolves, efficient SG&A management remains a key differentiator for sustained growth and profitability.
Cost Management Insights: SG&A Expenses for argenx SE and Iovance Biotherapeutics, Inc.
SG&A Efficiency Analysis: Comparing Alnylam Pharmaceuticals, Inc. and Supernus Pharmaceuticals, Inc.
Genmab A/S and Supernus Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Madrigal Pharmaceuticals, Inc. and Iovance Biotherapeutics, Inc.
Who Optimizes SG&A Costs Better? Grifols, S.A. or Iovance Biotherapeutics, Inc.
Who Optimizes SG&A Costs Better? Axsome Therapeutics, Inc. or Supernus Pharmaceuticals, Inc.
Verona Pharma plc vs Iovance Biotherapeutics, Inc.: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of Rhythm Pharmaceuticals, Inc. and Iovance Biotherapeutics, Inc.
SG&A Efficiency Analysis: Comparing Perrigo Company plc and Supernus Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Xenon Pharmaceuticals Inc. and Iovance Biotherapeutics, Inc.
Bausch Health Companies Inc. vs Iovance Biotherapeutics, Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Amicus Therapeutics, Inc. and Iovance Biotherapeutics, Inc.